A successful antenatal outcome in a patient with refractory Takayasu’s arteritis treated with tocilizumab throughout pregnancy—a case report

Abstract Takayasu’s arteritis (TA) is a rare form of large-vessel vasculitis for which tocilizumab (TCZ) may be administered in resistant or refractory disease. Current British Society of Rheumatology advice is to stop TCZ 3-months pre-conception. We report the case of a 33-year-old woman with exten...

Full description

Saved in:
Bibliographic Details
Published in:Oxford Medical Case Reports 2023-05, Vol.2023 (5), p.omad046
Main Authors: Khan, Behram, David, Trixy, Sussman, Jon, Simcox, Louise, Tower, Clare, Soh, Calvin, Bruce, Ian N
Format: Article
Language:English
Subjects:
Case Report
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Takayasu’s arteritis (TA) is a rare form of large-vessel vasculitis for which tocilizumab (TCZ) may be administered in resistant or refractory disease. Current British Society of Rheumatology advice is to stop TCZ 3-months pre-conception. We report the case of a 33-year-old woman with extensive TA treated with TCZ, azathioprine and glucocorticoids in pregnancy. She was closely monitored with MDT input and TCZ was continued throughout pregnancy as the benefits were thought to outweigh the risks. Our case also highlights the importance of accurate blood pressure monitoring in an appropriate anatomical location, given the extent of her disease. Our patient’s disease remained stable throughout the antenatal and post-partum period with a successful pregnancy outcome and no maternal or foetal complications. TCZ is suitable for select cases of refractory TA during pregnancy.
ISSN:2053-8855
2053-8855
DOI:10.1093/omcr/omad046